Postdoc positions in the Neurometabolic Diseases Laboratory, IDIBELL, Barcelona, Spain

Genomic Medicine for Rare Brain Diseases: from Genomic Diagnosis to Treatment through Brain Organoids

Two postdoctoral /staff scientists positions available at the Neurometabolic Lab at IDIBELL, Bellvitge Campus (http://www.idibell.cat/en/content/neurometabolic-diseases)in Barcelona, Spain, led by ICREA Professor Aurora Pujol. We apply Genomic Medicine from genomic diagnostics and gene discovery to therapeutics for rare brain metabolic diseases.

Position 1 is for a molecular geneticist with deep knowledge of genome analysis and interpretation, who aims at solving diagnostic Odysseys beyond conventional testing, using whole and long-read genomes, epigenomes, and transcriptomes. Ideal candidates will master bioinformatics tools for integrative multiomics analysis.

Position 2 is a for a cell biologist interested in organellar crosstalk, bioenergetics, immunology, aging and neuroscience, eager to work with patient-derived iPSC and brain organoids, in collaboration with Consiglio lab at Idibell. Multiomic approaches to decipher pathogenesis and the metabolic needs of the brain in development will be applied to find cures for rare metabolic diseases.

Enthusiastic and self-motivated team players with strong record of publications with several first author papers and excellent English communication skills are encouraged to apply. Salary commensurate to experience. Please submit a single PDF file with a cover letter, full CV and contact information of two references to Dr. Stéphane Fourcade and Prof. Aurora Pujol (sfourcade@idibell.cat, apujol@idibell.cat). Deadline is September 30th 2021, but interviews will start immediately. Follow us on Twitter: @PujolLab @consiglioLab

Related publications:

1. di Domenico A (2019). Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease. *Stem Cell Reports*. 12(2):213-229.
2. Pant DC et al. (2019) Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy. *J Clin Invest*, 129, 1240-1256.
3. García-Cazorla et al (2020) Impairment of the mitochondrial one-carbon metabolism enzyme SHMT2 causes a novel brain and heart developmental syndrome. *Acta Neuropathol*. 140(6):971-975.
4. Verdura et al (2021) Biallelic PI4KA variants cause a novel neurodevelopmental syndrome with hypomyelinating leukodystrophy. *Brain.* Aug 20:awab124

INSTITUT
D´INVESTIGACIÓ
BIOMÈDICA
DE BELLVITGE

Gran Via 199
08908 L'Hospitalet (Barcelona)
SPAIN

apujol@idibell.cat
www.idibell.cat

Tel: +34 932 607 137
Fax: +34 932 607 414